Universität zu Köln

Ceccon, Garry, Lazaridis, Lazaros, Stoffels, Gabriele ORCID: 0000-0001-7114-1941, Rapp, Marion, Weber, Manuel, Blau, Tobias, Lohmann, Phillip, Kebir, Sied, Herrmann, Ken, Fink, Gereon R. ORCID: 0000-0002-8230-1856, Langen, Karl-Josef ORCID: 0000-0003-1101-5075, Glas, Martin and Galldiks, Norbert ORCID: 0000-0002-2485-1796 (2018). Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. Eur. J. Nucl. Med. Mol. Imaging, 45 (9). S. 1626 - 1636. NEW YORK: SPRINGER. ISSN 1619-7089

Full text not available from this repository.

Abstract

We present our first clinical experience with O-(2-F-18-fluoroethyl)-l-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes. We retrospectively assessed 12 patients (mean age 51 +/- 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up. In all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 +/- 0.6, TBRmean 2.7 +/- 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI. FET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ceccon, Garry UNSPECIFIED UNSPECIFIED UNSPECIFIED Lazaridis, Lazaros UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoffels, Gabriele UNSPECIFIED orcid.org/0000-0001-7114-1941 UNSPECIFIED Rapp, Marion UNSPECIFIED UNSPECIFIED UNSPECIFIED Weber, Manuel UNSPECIFIED UNSPECIFIED UNSPECIFIED Blau, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Lohmann, Phillip UNSPECIFIED UNSPECIFIED UNSPECIFIED Kebir, Sied UNSPECIFIED UNSPECIFIED UNSPECIFIED Herrmann, Ken UNSPECIFIED UNSPECIFIED UNSPECIFIED Fink, Gereon R. UNSPECIFIED orcid.org/0000-0002-8230-1856 UNSPECIFIED Langen, Karl-Josef UNSPECIFIED orcid.org/0000-0003-1101-5075 UNSPECIFIED Glas, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Galldiks, Norbert UNSPECIFIED orcid.org/0000-0002-2485-1796 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-180381
DOI:	10.1007/s00259-018-3992-5
Journal or Publication Title:	Eur. J. Nucl. Med. Mol. Imaging
Volume:	45
Number:	9
Page Range:	S. 1626 - 1636
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1619-7089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language POSITRON-EMISSION-TOMOGRAPHY; AMINO-ACID PET; RESPONSE ASSESSMENT; O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET; RECURRENT GLIOBLASTOMA; MALIGNANT GLIOMAS; WORKING GROUP; BRAIN-TUMORS; PSEUDOPROGRESSION; THERAPY Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18038